display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 2nd line (L2)
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMblaze-370 ...
atezolizumab plus bevacizumab BACCI BACCI
atezolizumab plus cometinib IMblaze-370 ...
avelumab based treatment
avelumab alone SAMCO-PRODIGE 54

Study type: